Article
Medicine, General & Internal
Dalan Jing, Debo You, Ziyuan Liu, Wei Wang
Summary: Extranodal natural killer/T-cell lymphoma, nasal type can occur primarily in the orbit without involvement of the nasal cavity. Early discovery, biopsy, diagnosis, and appropriate treatment can successfully control tumors and improve prognosis.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Pathology
Han-Na Kim, Dae Sik Kim, Min Ji Jeon, Eun Sang Yu, Chul-Won Choi, Young Hyeh Ko
Summary: This case report describes a rare occurrence of excessive Epstein-Barr virus (EBV)-positive B cells in a patient with peripheral T cell lymphoma masquerading as nasopharyngeal extranodal NK/T cell lymphoma. The B cell population expanded after chemotherapy, forming EBV-positive diffuse large B cell lymphoma.
Review
Oncology
Renata de Oliveira Costa, Juliana Pereira, Luis Alberto de Padua Covas Lage, Otavio Cesar Guimaraes Baiocchi
Summary: Extranodal NK-/T-cell lymphoma (ENKTCL) is a rare and aggressive malignancy with racial and geographic variations worldwide. It primarily originates from extranodal sites, causes vascular damage and tissue destruction, and is associated with Epstein-Barr virus (EBV). Diagnosis requires pathological review and immunohistochemistry studies, including EBV-encoded small RNA (EBER) in situ hybridization. Accurate staging is essential using F-18-FDG-PET/CT, and treatment consists of combined modality therapy for localized cases and l-asparaginase-containing regimens for advanced-stage disease. Future strategies involve targeted therapies and improved patient identification, requiring international collaborations and clinical trials.
FRONTIERS IN ONCOLOGY
(2023)
Review
Medicine, General & Internal
John C. Reneau, Polina Shindiapina, Zachary Braunstein, Youssef Youssef, Miguel Ruiz, Saira Farid, Walter Hanel, Jonathan E. Brammer
Summary: Extranodal natural killer/T(NK/T)-cell lymphoma (ENKTL) is a rare subtype of non-Hodgkin lymphoma that usually presents with a nasal mass. Limited disease is treated with chemotherapy and radiation, while advanced stage disease is treated with L-asparaginase containing chemotherapy regimens. Modern radiation therapy techniques and the use of L-asparaginase in chemotherapy have improved outcomes, but relapse and relapse-related deaths remain frequent. Novel therapies have been evaluated for the treatment of this disease.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Yanxia He, Yan Gao, Liqin Ping, Haixia He, Cheng Huang, Bing Bai, Xiaoxiao Wang, Zhiming Li, Qingqing Cai, Yuhua Huang, Xueyi Pan, Wenbin Zeng, Yanan Liu, Huiqiang Huang
Summary: This study evaluated the efficacy and toxicity of anti-PD-1 antibody-based treatment in patients with NK/T-LAHS. The results showed that the combination of anti-PD-1 antibody and chemotherapy improved the overall response rate and was well tolerated.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Hematology
Eric Tse, Christopher P. Fox, Alexander Glover, Sang Eun Yoon, Won Seog Kim, Yok-Lam Kwong
Summary: NK/T-cell lymphomas predominantly arise from NK-cells and are commonly infected with Epstein Barr virus (EBV). They are rare lymphomas more prevalent in Asian and Central/South American populations. The diagnosis is established through histological and immunohistochemical examination, along with the presence of EBV in the tumor cells. Staging and plasma EBV DNA quantification are crucial for determining management and prognosis. Treatment options vary based on disease stage, with chemotherapy and radiotherapy being effective for early-stage disease and asparaginase-containing regimens and stem cell transplantation considered for advanced-stage disease. Salvage chemotherapy is largely ineffective for relapsed/refractory disease, and novel therapeutic approaches are being explored.
SEMINARS IN HEMATOLOGY
(2022)
Review
Microbiology
Miki Takahara, Takumi Kumai, Kan Kishibe, Toshihiro Nagato, Yasuaki Harabuchi
Summary: ENKTL-NT is commonly seen in Eastern Asia, with progressive necrotic lesions and poor prognosis. Diagnosis of ENKTL-NT requires CD56 immunostaining and EBER in situ hybridization, while monitoring can be done through serum EBV DNA levels. Despite being refractory, therapies such as concomitant chemoradiotherapy have improved the prognosis of ENKTL-NT.
Article
Pathology
Italo Francesco Aromolo, Carlo Pescia, Domenico Simeoli, Silvia Alberti Violetti, Valeria Ferla, Francesca Gaia Rossi, Giorgio Alberto Croci
Summary: This study presents the case of an 85-year-old man who developed an erythematous, subcutaneous nodule on the forehead while receiving ibrutinib for mantle cell lymphoma. Pathological analysis revealed the presence of extranodal NK/T-cell lymphoma, a rare subtype. Despite negative staging and comorbidities, a watchful waiting strategy was successful in achieving benign self-resolution and complete remission during the 4-year follow-up.
Article
Hematology
Won Seog Kim, Yasuhiro Oki, Seok Jin Kim, Sang Eun Yoon, Kirit M. Ardeshna, Yi Lin, Jia Ruan, Pierluigi Porcu, Jonathan E. Brammer, Eric D. Jacobsen, Dok Hyun Yoon, Cheolwon Suh, Felipe Suarez, John Radford, Lihua E. Budde, Jin Seok Kim, Emmanuel Bachy, Hun Ju Lee, Catherine M. Bollard, Arnaud Jaccard, Hye Jin Kang, Shannon Inman, Maryann Murray, Katherin E. Combs, Daniel Y. Lee, Ranjana Advani, Kurt C. Gunter, Cliona M. Rooney, Helen E. Heslop
Summary: The study conducted a phase II clinical trial of autologous EBV-specific T cell treatment (baltaleucel-T) in advanced, relapsed ENKTL patients. The results showed that this treatment demonstrated single-agent activity and improved survival outcomes in some patients.
ANNALS OF HEMATOLOGY
(2021)
Review
Oncology
Celeste Sanchez-Romero, Ronell Bologna-Molina, Oslei Paes de Almeida, Alan Roger Santos-Silva, Ana Carolina Prado-Ribeiro, Thais Bianca Brandao, Roman Carlos
Summary: ENKTCL-NT is an aggressive malignancy associated with EBV infection, typically affecting nasal or upper aerodigestive structures with poor prognosis. Recent advancements in diagnosis and treatment, including changes in chemotherapy regimens combined with radiotherapy, have significantly improved patient survival rates, especially in early stages.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Virology
Zheng Yan, Zhihua Yao, Haiying Wang, Shuna Yao, Xiaoxiao Wang, Yan Gao, Bing Bai, Junfeng Chu, Shuang Zhao, Xufeng Luo, Wenping Zhou, Jiuyang Zhang, Peipei Zhang, Huiqiang Huang, Yanyan Liu
Summary: This study found that plasma and peripheral blood mononuclear cell (PBMC) EBV-DNA have different clinical relevance in patients with extranodal NK/T-cell lymphoma (ENKTCL). PBMC EBV-DNA does not correlate with imaging-based disease assessment and should not be used for response evaluation and relapse monitoring. However, PBMC EBV-DNA still has prognostic value. Plasma EBV-DNA is strongly related to tumor status and is a sensitive marker in relapse monitoring compared to PET/CT and CT/MRI. Consideration of EBV-DNA kinetic patterns can help identify at-risk patients.
JOURNAL OF CLINICAL VIROLOGY
(2022)
Article
Virology
Zheng Yan, Zhihua Yao, Haiying Wang, Shuna Yao, Xiaoxiao Wang, Yan Gao, Bing Bai, Junfeng Chu, Shuang Zhao, Xufeng Luo, Wenping Zhou, Jiuyang Zhang, Peipei Zhang, Huiqiang Huang, Yanyan Liu
Summary: In patients with ENKTCL, plasma and PBMC EBV-DNA have different clinical relevance. Plasma EBV-DNA is more related to tumor status and has higher sensitivity in relapse monitoring. PBMC EBV-DNA does not correlate with imaging-based disease assessment but still holds prognostic value.
JOURNAL OF CLINICAL VIROLOGY
(2022)
Article
Pathology
Chih-Chi Chou, Cheng-Feng Tsao, Chun-Kai Liao, Huey-Ling You, Ming-Chung Wang, Wan-Ting Huang
Summary: This study analyzed the genomic diversity of EBV in NKTCL and its correlation with HLA-restricted epitope variations in the Taiwanese population. The highest density of non-synonymous variants was detected in the EBNA3B gene, and several T-cell epitopes showed variations. The frequency of variation in HLA-restricted epitopes among common HLA types in the Taiwanese population was significantly low, while the frequency of anchor residue variations was significantly high.
EXPERIMENTAL AND MOLECULAR PATHOLOGY
(2021)
Article
Immunology
Yao Wang, Minan Zhang, Qingfeng Xue, Huan Zhou, Jie Chen, Hong Wang, Yaping Zhang, Wenyu Shi
Summary: Chronic active Epstein-Barr virus disease (CAEBV) is a systemic lymphoproliferative disorder closely associated with Epstein-Barr virus (EBV) infection. CAEBV can progress to extranodal natural killer/T-cell lymphoma (ENKTL) and has a poor outcome. The efficacy and safety of PD-1 inhibitor therapy in EBV-associated diseases is unclear. This report presents a case of rapid disease progression and hyperinflammation following PD-1 inhibitor therapy in a patient diagnosed with ENKTL secondary to CAEBV.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Chantana Polprasert, Yasuhide Takeuchi, Hideki Makishima, Kitsada Wudhikarn, Nobuyuki Kakiuchi, Nichthida Tangnuntachai, Thamathorn Assanasen, Wimonmas Sitthi, Hamidah Muhamad, Panisinee Lawasut, Sunisa Kongkiatkamon, Udomsak Bunworasate, Koji Lzutsu, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Satoru Miyano, Seishi Ogawa, Kenichi Yoshida, Ponlapat Rojnuckarin
Summary: ENKTCLs are aggressive lymphomas predominantly affecting Asians. Defective HLA-A gene is recurrently identified in ENKTCLs and associated with disease progression, suggesting immune escape as a pathogenic mechanism.
LEUKEMIA & LYMPHOMA
(2021)
Article
Biophysics
Ayumi Fujimoto, Fumihiro Ishida, Koji Izutsu, Satoshi Yamasaki, Dai Chihara, Junji Suzumiya, Tetsuo Mitsui, Noriko Doki, Hitoshi Sakai, Hikaru Kobayashi, Junya Kanda, Takahiro Fukuda, Yoshiko Atsuta, Ritsuro Suzuki
Summary: Aggressive NK-cell leukemia (ANKL) has a poor prognosis and allo-HSCT is currently the only curative treatment. Analysis of ANKL patients who underwent first allo-HSCT showed better overall survival for those who achieved complete or partial response at the time of transplant, as well as for those receiving cord blood stem cells. Patients achieving event-free survival at 12 months after allo-HSCT had good outcomes with high overall survival rates.
BONE MARROW TRANSPLANTATION
(2021)
Article
Pathology
Ayumi Fujimoto, Fumiyoshi Ikejiri, Fumiko Arakawa, Shunsuke Ito, Yusuke Okada, Fumimasa Takahashi, Shinichiro Matsuda, Takahiro Okada, Masaya Inoue, Tsutomu Takahashi, Takaaki Miyake, Riruke Maruyama, Koichi Ohshima, Junji Suzumiya, Ritsuro Suzuki
Summary: This study reports a rare case of concurrent B-LBL and FL in a 39-year-old man, with investigation into the clonal relationship between the two histological subtypes. The findings suggest that acquisition of MYC gene rearrangement is crucial for the lymphoblastic transformation of FL.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
(2021)
Article
Oncology
Tsutomu Takahashi, Ritsuro Suzuki, Go Yamamoto, Hideyuki Nakazawa, Mitsutoshi Kurosawa, Tsutomu Kobayashi, Masaya Okada, Takashi Akasaka, Sung-Won Kim, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta, Junji Suzumiya
Summary: The study suggests that auto-SCT may be effective for MYC-R DLBCL, while outcomes of allo-SCT are unsatisfactory due to high non-relapse mortality and early relapse, further accumulation of patients is necessary to clarify the role of allo-SCT for MYC-R DLBCL.
HEMATOLOGICAL ONCOLOGY
(2021)
Article
Oncology
Katsuhiro Miura, Hideki Tsujimura, Yasufumi Masaki, Masaki Iino, Jun Takizawa, Yoshinobu Maeda, Kazuhiko Yamamoto, Shinobu Tamura, Akiyo Yoshida, Hideo Yagi, Isao Yoshida, Koichi Kitazume, Taro Masunari, Ilseung Choi, Yasutaka Kakinoki, Ritsuro Suzuki, Tadashi Yoshino, Shigeo Nakamura, Yoshihiro Hatta, Takashi Yoshida, Masatoshi Kanno
Summary: The study evaluated the efficacy and safety of consolidation therapy with Y-90-IT after re-induction therapy with BR in patients with previously treated FL. Among the 22 patients who received Y-90-IT consolidation, the 2-year PFS rate was 59%, and patients whose remission lasted ≥2 years had a significantly higher PFS rate. Major adverse events were hematological toxicities, but acceptable, and the estimated 2-year overall survival after consolidation was 95%.
HEMATOLOGICAL ONCOLOGY
(2021)
Article
Oncology
Atae Utsunomiya, Koji Izutsu, Tatsuro Jo, Shinichiro Yoshida, Kunihiro Tsukasaki, Kiyoshi Ando, Ilseung Choi, Yoshitaka Imaizumi, Koji Kato, Mitsutoshi Kurosawa, Shigeru Kusumoto, Takashi Miyagi, Eiichi Ohtsuka, Osamu Sasaki, Hirohiko Shibayama, Kazuya Shimoda, Yasushi Takamatsu, Kuniko Takano, Kentaro Yonekura, Shinichi Makita, Jun Taguchi, Mireille Gillings, Hiroshi Onogi, Kensei Tobinai
Summary: This multicenter, prospective phase IIb trial evaluated the efficacy and safety of Tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma (ATLL) in Japan. Results showed that Tucidinostat had a meaningful treatment effect for R/R ATLL patients, although adverse events were common.
Article
Oncology
Noriko Fukuhara, Youko Suehiro, Harumi Kato, Shigeru Kusumoto, Cinthya Coronado, Erica Rappold, Wanying Zhao, Jia Li, Aidan Gilmartin, Koji Izutsu
Summary: Parsaclisib, a potent PI3K delta inhibitor, showed clinical benefit in Japanese patients with relapsed or refractory B-cell malignancies. The drug demonstrated comparable pharmacokinetics between Japanese and Western patients, and achieved high objective response rate in follicular lymphoma and marginal zone lymphoma.
Article
Hematology
Koji Izutsu, Shinichi Makita, Kisato Nosaka, Makoto Yoshimitsu, Atae Utsunomiya, Shigeru Kusumoto, Satoko Morishima, Kunihiro Tsukasaki, Toyotaka Kawamata, Takaaki Ono, Shinya Rai, Hiroo Katsuya, Jun Ishikawa, Hironori Yamada, Kazunobu Kato, Masaya Tachibana, Yasuyuki Kakurai, Nobuaki Adachi, Kensei Tobinai, Kentaro Yonekura, Kenji Ishitsuka
Summary: This study evaluated the efficacy and safety of valemetostat, an inhibitor of EZH2 and EZH1, in treating relapsed or refractory ATL. The results showed that valemetostat demonstrated promising efficacy and tolerability in heavily pretreated patients with R/R ATL, warranting further investigation.
Article
Oncology
Takaaki Ono, Naoto Takahashi, Masahiro Kizaki, Tatsuya Kawaguchi, Ritsuro Suzuki, Kazuhito Yamamoto, Kazunori Ohnishi, Tomoki Naoe, Itaru Matsumura
Summary: Age and comorbidities should be taken into consideration when selecting TKIs for first-line treatment in CML-CP patients. This study found that the choice between imatinib and second-generation TKIs did not significantly impact treatment outcomes, regardless of age. However, older patients had lower overall survival rates compared to younger patients.
Article
Oncology
Michael L. Wang, Wojciech Jurczak, Pier Luigi Zinzani, Toby A. Eyre, Chan Y. Cheah, Chaitra S. Ujjani, Youngil Koh, Koji Izutsu, James N. Gerson, Ian Flinn, Benoit Tessoulin, Alvaro J. Alencar, Shuo Ma, David Lewis, Ewa Lech-Maranda, Joanna Rhodes, Krish Patel, Kami Maddocks, Nicole Lamanna, Yucai Wang, Constantine S. Tam, Talha Munir, Hirokazu Nagai, Francisco Hernandez-Ilizaliturri, Anita Kumar, Timothy S. Fenske, John F. Seymour, Andrew D. Zelenetz, Binoj Nair, Donald E. Tsai, Minna Balbas, Richard A. Walgren, Paolo Abada, Chunxiao Wang, Junjie Zhao, Anthony R. Mato, Nirav N. Shah
Summary: This study evaluated the safety and efficacy of Pirtobrutinib, a noncovalent BTK inhibitor, in patients with mantle-cell lymphoma who had previously received covalent BTK inhibitors. The results showed that Pirtobrutinib demonstrated durable efficacy and was well tolerated in this heavily pretreated patient population.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Letter
Biophysics
Risa Koresawa-Shimizu, Ritsuro Suzuki, Yasufumi Uehara, Nobuhiro Hiramoto, Masashi Sawa, Takahiro Fukuda, Keisuke Kataoka, Yoshinobu Kanda, Tatsuo Oyake, Yasushi Kubota, Naoyuki Uchida, Shingo Yano, Hikaru Kobayashi, Junji Tanaka, Yoshiko Atsuta, Eisei Kondo
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Koji Izutsu, Takahiro Kumode, Junichiro Yuda, Hirokazu Nagai, Yuko Mishima, Youko Suehiro, Kazuhito Yamamoto, Tomoaki Fujisaki, Kenji Ishitsuka, Kenichi Ishizawa, Takayuki Ikezoe, Momoko Nishikori, Daigo Akahane, Jiro Fujita, Minh Dinh, David Soong, Hidehisa Noguchi, Jeppe Klint Buchbjerg, Elena Favaro, Noriko Fukuhara
Summary: This study presented the results of epcoritamab monotherapy in Japanese patients, showing durable treatment responses and manageable safety profile. The drug has potential therapeutic effects in relapsed or refractory diffuse large B-cell lymphoma.
Letter
Hematology
Koji Izutsu, Kazuhito Yamamoto, Koji Kato, Takayuki Ishikawa, Noriko Fukuhara, Yasuhito Terui, Ilseung Choi, Sumiko Okubo, Natsumi Ogawa, Mizu Sakai, Yasuko Nishimura, Brenda Chyla, Yan Sun, Dai Maruyama
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Wataru Munakata, Koji Izutsu, Yuko Mishima, Hirokazu Nagai, Yuko Ishihara, Junji Suzumiya, Yuzuru Kanakura, Toshihiro Nanki, Takeshi Miyake, Atsuko Kawasaki, Tatsuya Yoshinaga, Kenichi Ishizawa
Summary: This study assessed the tolerability, safety, and pharmacokinetics of mosunetuzumab in Japanese patients with relapsed/refractory B-cell NHL. The results demonstrated that mosunetuzumab has acceptable safety and antitumor activity in Japanese patients, and the recommended Phase II dose was identified.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Carla Casulo, Armando Santoro, Guillaume Cartron, Kiyoshi Ando, Javier Munoz, Steven Le Gouill, Koji Izutsu, Simon Rule, Pieternella Lugtenburg, Jia Ruan, Luca Arcaini, Marie-Laure Casadebaig, Brian Fox, Nurgul Kilavuz, Nils Rettby, Justine Dell'Aringa, Lilia Taningco, Richard Delarue, Myron Czuczman, Thomas Witzig
Summary: The immune checkpoint inhibitor durvalumab shows potential as a strategy for enhancing immune responses and improving standard therapies in patients with hematologic malignancies. This study evaluated the safety and efficacy of durvalumab in combination with standard-of-care therapies for lymphoma or chronic lymphocytic leukemia (CLL) and found limited benefits of durvalumab monotherapy or combination therapy.
